Skip to content

Company

About us

GATC Health transforms the way drugs are created, developed and financed. Verified at 91% specificity and 86% sensitivity, and trusted by the world’s largest insurance marketplace, our Operon™ platform creates innovative therapeutic solutions, extends pipelines, and optimizes assets. Like a FICO® Score for drug discovery and development, our Derisq™ AI Report delivers objective, Operon-powered insights that help biopharma leaders and investors prioritize assets and predict outcomes – all before committing capital or entering the clinic.

The Minds Behind the Innovation

GATC Health brings together the industry’s leading experts in AI, biology, drug development and business strategy. With collective decades of hands-on experience, we take an objective, pragmatic view of drug candidates and work closely with you, shaping strategy and pressure-testing results to help you bring better therapies to patients, faster.

Dr. Rahul Gupta

President

Ian Jenkins

Chief Science Officer

John Stroh

Chief Executive Officer

Jayson Uffens

Chief Technology Officer

Jeff Moses

Chief Marketing Officer

Tyrone Lam

Chief Business Officer

Eric J. Mathur

Chief Innovation Officer

Johnathan Lakey, PhD, MSM

Chair of Scientific Advisory Board

Robert Tinder, PhD

Head of Chemical Research and Development

Eugene O’Bryan

Chief Operations Officer

Waldemar Lernhardt, PhD

Vice President of Scientific Operations

Vaishnavi Narayan

Head of AI Engineering

Advisors

Our board of advisors is a powerhouse of knowledge and experience. Comprising esteemed researchers, medical doctors, biotech executives, and policy experts, they offer invaluable guidance in steering GATC’s mission.

Herbert Boyer

Herbert Boyer

Herbert Boyer headshot

Herbert Boyer

  • Co-founded Genentech (first biotech company to go public)
  • Co-discovered methods that founded genetic engineering
  • Numerous awards including the Albert Lasker Award for Medical Research, Industrial Research Institute Achievement Award, the National Medal of Technology, National Medal of Science
Dr. Tomas Philipson 

Dr. Tomas Philipson 

Dr. Tomas Philipson  headshot

Dr. Tomas Philipson 

  • Former Acting Chairman, U.S. Council of Economic Advisers 
  • Daniel Levin Chair in Public Policy, University of Chicago Internationally recognized health economist and frequent contributor to Forbes and major media outlets 
  • Internationally recognized health economist and frequent contributor to Forbes and major media outlets 
  • Ph.D. in Economics, University of Pennsylvania 

Dr. Richard Schatz

Dr. Richard Schatz

Dr. Richard Schatz headshot

Dr. Richard Schatz

  • Research Director of Cardiovascular Interventions, Scripps Heart, Lung & Vascular Center 
  • Co-inventor of the Palmaz-Schatz Coronary Stent, revolutionizing treatment for coronary artery disease 
  • Recipient of the Russ Prize for Bioengineering and inductee of the National Inventors Hall of Fame 

Dr. Lin Yu

Dr. Lin Yu

Dr. Lin Yu headshot

Dr. Lin Yu

  • Managing Director, Royalty Private Credit with two decades of healthcare investment and advisory experience 
  • Former Managing Director, Oppenheimer; Head of Medtech and Life Science & Tools practices 
  • Prior roles at BTIG, KKR, DRI Capital, and Cowen & Co. focused on healthcare royalty and finance 
  • Ph.D. and M.S. in Chemical Engineering, Columbia University; B.S., The Cooper Union 
Bob Davidson 

Bob Davidson 

Bob Davidson  headshot

Bob Davidson 

  • Founder of Davidson & Associates; acquired Blizzard Entertainment, led landmark sale, and launched Math Blaster™ 
  • Chairman and Co-Founder, Spree AI; pioneering AI-driven fashion retail technology 
  • Philanthropist and author; founded Davidson Academy for profoundly gifted youth, award-winning education advocate 
  • Degrees from Purdue (BS), George Washington (JD), UCLA (MBA); honorary doctorate, University of Nevada 
Uri Litvak

Uri Litvak

Uri Litvak headshot

Uri Litvak

  • Managing Partner, Litvak Law Groups 
  • Former Assistant General Counsel, AIG; Director and Legal Counsel, Cendant Corporation 
  • Nearly three decades of experience in the areas of M&A, corporate law, securities, and corporate finance 
  • JD, University of Miami; BA, New York University, magna cum laude 
Phil Trad

Phil Trad

Phil Trad headshot

Phil Trad

  • Former President/General Counsel at CEATS, Krystal Digital; expertise in patent development and FDA approvals 
  • Represented clients including General Electric Corporation, NBC Studios, Black and Decker, Budget Rent-A-Car, Hertz and MGM Corporation 
  • Experienced business litigator in California since 1978, specializing in insurance defense and corporate law  
  • JD, Western State University College of Law; BA, California State University, Fullerton 
Dr. Jack Lewin

Dr. Jack Lewin

Dr. Jack Lewin headshot

Dr. Jack Lewin

  • Administrator, Hawaii State Health Planning Development, Sr Advisor to Governor
  • Former CEO, American College of Cardiology, California Medical Association
  • Former President & CEO of Cardiovascular Research Foundation

“GATC’s AI has enabled this first-of-a-kind combination of financing protected by insurance in case the clinical trial is not successful. The early response from biotech companies and large brokerage firms for this product has exceeded our expectations which represents the pent-up demand for this innovative financing program.”

Ben Canagaretna

Global Managing Director of Acrisure Re Corporate Advisory & Solutions

Forward thinking and 
future-focused

We understand who we serve. Our partners are pioneers who see a problem and try to find a solution. And so do we. We step up to the challenge with discipline and imagination.

Unmatched predictive power

Break the cycle of risk, cost and delay. Bring scientific integrity and financial confidence to every decision. GATC Health’s predictive analytics aren’t just trusted by scientists. They’re relied upon by some of the largest institutions in the world. Whether you’re an investor, insurer or developer, GATC Health helps you make smarter, lower-risk choices.

87%
Sensitivity
Outperforms industry average by 20x in early-stage drug success predictions
10-18
months
to progress through pre-clinical